The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2019 | Results of Phase III study into treatment for NSCLC

Name: Results of Phase III study into treatment for NSCLC
Uploaded: 2019-06-03T00:00:00Z
Duration: 2 min 31 s
Description: Vanita Noronha, MBBS, MD, DM, of the Tata Memorial Center, Mumbai, India, discusses the results of a Phase III study investigating gefitinib versus combination therapy in the treatment of non-small cell lung cancer (NSCLC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Vanita Noronha • 3 Jun 2019

ASCO 2019

Lung Cancer Gefitinib

Vanita Noronha, MBBS, MD, DM, of the Tata Memorial Center, Mumbai, India, discusses the results of a Phase III study investigating gefitinib versus combination therapy in the treatment of non-small cell lung cancer (NSCLC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.